Use of fondaparinux (ARIXTRA®) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II

Saved in:
Bibliographic Details
Published inNephrology, dialysis, transplantation Vol. 20; no. 2; pp. 444 - 446
Main Authors Haase, Michael, Bellomo, Rinaldo, Rocktaeschel, Jens, Ziemer, Sabine, Kiesewetter, Holger, Morgera, Stanislao, Neumayer, Hans-H.
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.02.2005
Oxford Publishing Limited (England)
Subjects
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Anticoagulants - therapeutic use
Associated diseases and complications
Biological and medical sciences
Diabetes. Impaired glucose tolerance
dialysis
Emergency and intensive care: renal failure. Dialysis management
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
fondaparinux
Glomerulonephritis
Heparin - adverse effects
heparin-induced thrombocytopaenia type II
Humans
Intensive care medicine
Kidney Failure, Chronic - surgery
Kidney Transplantation
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Polysaccharides - therapeutic use
Thrombocytopenia - drug therapy
Thrombocytopenia - etiology
Thrombosis - drug therapy
Treatment Outcome
Kidney disease
Human
Extrarenal dialysis
fondaparinux
Urinary system disease
Hemodialysis
Renal failure
heparin-induced thrombocytopaenia type II
Glycosaminoglycan
Anticoagulant
Dialysis
Heparin
Online AccessGet full text

Cover

More Information
Bibliography:local:gfh544
istex:759274FA21268C310805328C2C3A70170274CAB5
Correspondence and offprint requests to: M. Haase, MD, Universitätsklinikum Charité der Humboldt Universität zu Berlin, Medizinische Klinik mit Schwerpunkt Nephrologie am CCM, Schumannstrasse 20/21, 10117 Berlin, Germany. Email: michael.haase@charite.de
ark:/67375/HXZ-WJQ9RMVG-D
ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/gfh544